The treatment of early Parkinson's disease: levodopa rehabilitated
Identifieur interne : 000070 ( Main/Exploration ); précédent : 000069; suivant : 000071The treatment of early Parkinson's disease: levodopa rehabilitated
Auteurs : Annemarie Vlaar [Pays-Bas] ; Ad Hovestadt [Pays-Bas] ; Teus Van Laar [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas]Source :
- Practical Neurology [ 1474-7758 ] ; 2011-06.
Abstract
Many clinicians regard levodopa as a last resort in the symptomatic treatment of Parkinson's disease. Here we critically review the arguments that are typically used to postpone the start of levodopa for as long as possible. We will point out that most concerns are invalid. Levodopa remains the most effective and best tolerated Parkinson's drug to date, and should have an important role in all therapeutic strategies, both as monotherapy in early Parkinson's disease and as part of combination therapy in advanced disease. Regardless of disease stage, the choice of a particular drug should not be driven by fear of long term complications but by the clinical condition of the patient at the time, with an emphasis on functioning in everyday life and any comorbidity. A ‘phobia’ for levodopa—or, indeed, for any other antiparkinsonian medication—is unacceptable according to current evidence.
Url:
DOI: 10.1136/practneurol-2011-000011
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>The treatment of early Parkinson's disease: levodopa rehabilitated</title><author><name sortKey="Vlaar, Annemarie" sort="Vlaar, Annemarie" uniqKey="Vlaar A" first="Annemarie" last="Vlaar">Annemarie Vlaar</name></author><author><name sortKey="Hovestadt, Ad" sort="Hovestadt, Ad" uniqKey="Hovestadt A" first="Ad" last="Hovestadt">Ad Hovestadt</name></author><author><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name></author><author><name sortKey="Bloem, Bastiaan R" sort="Bloem, Bastiaan R" uniqKey="Bloem B" first="Bastiaan R" last="Bloem">Bastiaan R. Bloem</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4D88684D2EFFE6FA550959FDB111FCB9BA6FCC34</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1136/practneurol-2011-000011</idno><idno type="url">https://api.istex.fr/document/4D88684D2EFFE6FA550959FDB111FCB9BA6FCC34/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001A82</idno><idno type="wicri:Area/Main/Curation">001823</idno><idno type="wicri:Area/Main/Exploration">000070</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">The treatment of early Parkinson's disease: levodopa rehabilitated</title><author><name sortKey="Vlaar, Annemarie" sort="Vlaar, Annemarie" uniqKey="Vlaar A" first="Annemarie" last="Vlaar">Annemarie Vlaar</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, Donders Institute for Brain Cognition and Behaviour, Nijmegen Medical Centre, Radboud University, Nijmegen</wicri:regionArea><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Hovestadt, Ad" sort="Hovestadt, Ad" uniqKey="Hovestadt A" first="Ad" last="Hovestadt">Ad Hovestadt</name><affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, Meander Medisch Centrum, Amersfoort</wicri:regionArea><wicri:noRegion>Amersfoort</wicri:noRegion></affiliation></author><author><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, University Medical Centre Groningen, University of Groningen, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Bloem, Bastiaan R" sort="Bloem, Bastiaan R" uniqKey="Bloem B" first="Bastiaan R" last="Bloem">Bastiaan R. Bloem</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Neurologist, Department of Neurology, Donders Institute for Brain Cognition and Behaviour, Nijmegen Medical Centre, Radboud University, Nijmegen</wicri:regionArea><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Practical Neurology</title><title level="j" type="abbrev">Pract Neurol</title><idno type="ISSN">1474-7758</idno><idno type="eISSN">1474-7766</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2011-06">2011-06</date><biblScope unit="volume">11</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="145">145</biblScope></imprint><idno type="ISSN">1474-7758</idno></series><idno type="istex">4D88684D2EFFE6FA550959FDB111FCB9BA6FCC34</idno><idno type="DOI">10.1136/practneurol-2011-000011</idno><idno type="href">practneurol-11-145.pdf</idno><idno type="ArticleID">practneurol11</idno><idno type="local">practneurol;11/3/145</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1474-7758</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Many clinicians regard levodopa as a last resort in the symptomatic treatment of Parkinson's disease. Here we critically review the arguments that are typically used to postpone the start of levodopa for as long as possible. We will point out that most concerns are invalid. Levodopa remains the most effective and best tolerated Parkinson's drug to date, and should have an important role in all therapeutic strategies, both as monotherapy in early Parkinson's disease and as part of combination therapy in advanced disease. Regardless of disease stage, the choice of a particular drug should not be driven by fear of long term complications but by the clinical condition of the patient at the time, with an emphasis on functioning in everyday life and any comorbidity. A ‘phobia’ for levodopa—or, indeed, for any other antiparkinsonian medication—is unacceptable according to current evidence.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li></country><region><li>Groningue (province)</li><li>Gueldre</li></region><settlement><li>Groningue</li><li>Nimègue</li></settlement></list><tree><country name="Pays-Bas"><region name="Gueldre"><name sortKey="Vlaar, Annemarie" sort="Vlaar, Annemarie" uniqKey="Vlaar A" first="Annemarie" last="Vlaar">Annemarie Vlaar</name></region><name sortKey="Bloem, Bastiaan R" sort="Bloem, Bastiaan R" uniqKey="Bloem B" first="Bastiaan R" last="Bloem">Bastiaan R. Bloem</name><name sortKey="Hovestadt, Ad" sort="Hovestadt, Ad" uniqKey="Hovestadt A" first="Ad" last="Hovestadt">Ad Hovestadt</name><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000070 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000070 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4D88684D2EFFE6FA550959FDB111FCB9BA6FCC34
|texte= The treatment of early Parkinson's disease: levodopa rehabilitated
}}
| This area was generated with Dilib version V0.6.23. |  |